Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS)
Authors:
- Silvia CorcioneSilvia Corcione
- Tommaso LupiaTLTommaso Lupia
- Carlo PallottoCPCarlo Pallotto
- Daniele Roberto GiacobbeDaniele Roberto Giacobbe
- Ilaria De BenedettoIBIlaria De Benedetto
- Giacomo StroffoliniGSGiacomo Stroffolini
- Simone Mornese PinnaSPSimone Mornese Pinna
- Carlo TasciniCarlo Tascini
- Matteo BassettiMatteo Bassetti
- Francesco Giuseppe De RosaFRFrancesco Giuseppe De Rosa
- on behalf of SITA GIOVANI (Young Investigators Group of the Società Italiana Terapia Antinfettiva)OAon behalf of SITA GIOVANI (Young Investigators Group of the Società Italiana Terapia Antinfettiva)
Open Access
- 2 January 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (1) , 56
Abstract
Background: infective endocarditis (IE) remains a severe disease frequently encountered in clinical practice and often requiring interdisciplinary medical and surgical management. This national survey aims to describe the clinical prescribing habits of the use of daptomycin in the setting of IE and the possible role for combination therapy with beta-lactams. Methods: The study was a cross-sectional internet-based questionnaire survey on therapy with daptomycin. The questionnaire was designed with closed-ended questions and distributed using the SurveyMonkey® platform between October 2019 to December 2020. Results: 55 clinicians from twelve Italians regions joined the questionnaire. The survey reported use of daptomycin as first-line choice in 31.48% of cases and as the first-line anti-MRSA agent in 44.44%. The empiric use of daptomycin was stated in the high suspicion of MRSA rather than MSSA, enterococcal or streptococcal IE. The rationale of daptomycin for the empirical treatment of native and prosthetic valve IE was mostly the possibility of administering an aminoglycoside-sparing combination regimen, high bacterial killing rate and high clinical efficacy. Conclusions: In conclusion, in selected patients, daptomycin could be a feasible option for the treatment of infective endocarditis in line with data from the European registry of daptomycin.Keywords
This publication has 33 references indexed in Scilit:
- A Current Perspective on Daptomycin for the Clinical MicrobiologistClinical Microbiology Reviews, 2013
- Impact of a Multidisciplinary Management Strategy on the Outcome of Patients With Native Valve Infective EndocarditisThe American Journal of Cardiology, 2013
- Daptomycin for outpatient parenteral antibiotic therapy: a European registry experienceInternational Journal of Antimicrobial Agents, 2013
- Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort StudyClinical Infectious Diseases, 2013
- Daptomycin for the treatment of infective endocarditis: results from a European registryJournal of Antimicrobial Chemotherapy, 2012
- Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 2012
- Dramatic Reduction in Infective Endocarditis–Related Mortality With a Management-Based ApproachArchives of internal medicine (1960), 2009
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolatesJournal of Antimicrobial Chemotherapy, 2008
- Infective endocarditis in the real world: the Italian Registry of Infective Endocarditis (Registro Italiano Endocardite Infettiva – RIEI)Journal of Cardiovascular Medicine, 2008
- Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused byStaphylococcus aureusNew England Journal of Medicine, 2006